Cost-Utility Analysis of adding daratumumab to bortezomib plus dexamethasone to treat Relapsed/Refractory Multiple Myeloma in Egypt
Background: According to the CASTOR trial, DARA is shown to be effective as a second line
for RRMM patients either as monotherapy or in combination with the gold standard regimen …
for RRMM patients either as monotherapy or in combination with the gold standard regimen …